Introduction
Like other epithelial cancers, head and neck carcinogenesis appears to evolve through a multistep process that involves biomolecular changes caused by carcinogen exposure, ensuing premalignant lesions and consequent invasive carcinoma (1) (2) (3) . The spectrum of histological changes occurring in this process has been cumulatively designated squamous intraepithelial lesions (SILs), ranging from squamous hyperplasia to carcinoma in situ (CIS) (4, 5) . One of the most important issues of SILs is the risk of malignant transformation. In their evolution, some SILs are self-limiting and reversible, some persist, and some progress to squamous carcinoma despite careful follow-up and treatment.
Although lesions with dysplastic features are thought to be at a higher cancer risk, some cancers develop from lesions lacking dysplastic changes. Hence, it is often difficult for clinicians to agree on the most appropriate therapeutic option have been considered to be the best candidate genes responsible for the 11q13-associated tumor aggressiveness on the basis of their biological roles and also their frequent co-amplification and overexpression in various cancers (8, 9) . CTTN encodes the actin-binding protein cortactin that regulates membrane dynamics, actin network assembly, cell-cell adhesion, invadopodia formation and matrix degradation, thereby promoting cell motility and invasion 
Materials and Methods

Patients and tissue specimens
Surgical tissue specimens from patients who were diagnosed of laryngeal dysplasia at the Hospital Universitario Central de Asturias between 1996 and 2004 were retrospectively collected, following institutional review board guidelines. Patients must meet the following criteria to be included in the study:
i) pathological diagnosis of laryngeal dysplasia; ii) with lesions of the vocal folds iii) no previous history of head and neck cancer; iv) complete excisional biopsy of the lesion; and v) a minimum follow-up of five years (or until progression to malignancy occurred). 95 patients who met these criteria were included in this study. Patients were followed up every two months in the first six months after completing the treatment, every three months until the second year, and every six months thereafter.
Excisional biopsy of lesions was carried out by using stripping microflap technique with cold instruments. A complete macroscopic exeresis of the lesion was performed in all cases, but the microscopic margins were not addressed.
Representative tissue sections were obtained from archival, paraffin-embedded blocks and the histological diagnosis was confirmed by an experienced pathologist (M.F.F.). The premalignant lesions were classified into the categories of mild, moderate or severe dysplasia following the WHO classification (5). Tumor blocks were also obtained from those patients who developed an invasive carcinoma. Normal laryngeal epithelium obtained from non-oncologic surgery (phonosurgery) was used as control. 
Gene amplification analysis
The protocol for DNA extraction from paraffin-embedded tissue sections has been described elsewhere (25). DNA extracted from normal mucosa obtained from non-oncologic patients was used as calibrator sample. 
Immunohistochemistry
The formalin-fixed, paraffin-embedded tissues were cut into 3-μm sections and method. Cox proportional hazards models were utilized for univariate and multivariate analyses. The hazard ratios (HR) with 95% confidence interval (CI) and P values were reported. All tests were two-sided. P values of .05 were considered statistically significant.
Results
Patient characteristics
All patients were men, with a mean age of 64 years (range 36-83 years). All of them were active or old smokers, and 43 were also habitual alcohol drinkers.
The mean tobacco consumption was 55 packs-year (range 15-110 packs-year).
After the diagnosis, all the patients that were active smokers received smoking cessation advice; however, 17 of them continued smoking. Of the 95 patients included in the study, ten patients with a diagnosis of premalignant lesion and cancer within the next six months were excluded from the study and three additional patients were also excluded due to the lack of tissue block/quality.
For the 82 remaining patients, 12 (15%) lesions were classified as mild dysplasia, 26 (32%) as moderate dysplasia, and 44 (54%) as severe dysplasia/carcinoma "in situ" (CIS). During the follow-up period, 28 (34%) of 82 patients developed an invasive carcinoma at the biopsy site and 12 patients (15%) required repeat resection of laryngeal dysplasias (Supplementary Data; Table S1 ). All available tissue blocks were collected for analysis.
The mean time to cancer diagnosis in the cases that progressed was 28 months (range 11 to 66 months). No significant differences attributable to age were packs-year, compared to 53.7 packs-year for those who did not develop cancer (P = .56). Similarly, no significant differences in laryngeal cancer risk were observed (P =.77) between the subgroup of patients who continued smoking (35%, 6 of 17 cases) and those who ceased smoking (33%, 22 of 65 cases).
CTTN and FAK protein expression in the early stages of laryngeal tumorigenesis
Immunohistochemical analysis of CTTN and FAK protein expression was performed on a set of 82 laryngeal dysplasias. Sections selected for study also contained normal epithelia as internal controls. Normal epithelia showed weak CTTN staining in the most differentiated layers, whereas positive FAK expression was restricted to the basal cell layer (Fig 1A-B Table 1 ). FAK expression also correlated significantly (Spearman's correlation coefficient 0.742; P < .001; Table 1 ). Overall, we observed that CTTN and FAK expression was maintained or further augmented in the tumor compared to the patient-matched preinvasive lesion (Table 1 and Supplementary Data; Table S1 ). In addition, a high level of concordance was found when comparing CTTN and FAK protein scores in patients who developed various laryngeal lesions (Supplementary Data; Table S1 ). In those cases with discordant data the highest score was assigned as final score. In addition, we found a strong positive relationship between CTTN gene amplification and protein expression (P = .007; Supplementary Data; Table S2 ). Fig 2C and Supplementary Data S4) .
Associations with laryngeal cancer risk
There was no statistically significant correlation in this cohort between the histopathological grade and the risk of progression to laryngeal cancer (P = .378; Table 2 ), although severe dysplasias showed a higher cancer risk (HR = 1.763, 95% CI 0.519 to 5.989; P = .364; Table 3 ).
Interestingly, we found that increased CTTN and FAK protein scores (from 0 to 3) significantly correlated with an increased laryngeal cancer risk (logrank P = .048 and P = .020, respectively; Fig 3A-B) . Since lesions with strong CTTN and FAK expression (score 3) showed the highest risk of progression, this was used as a cutoff point in our subsequent analyses (P = .016 and P = .004, respectively; Table 2 ). Consistent with these results, patients carrying strong CTTN-expressing lesions and strong FAK-expressing lesions experienced a significantly higher laryngeal cancer incidence than those with weak to moderate expression (log-rank P = .006 and P = .001, respectively; Fig   3C-D) . The simultaneous analysis of CTTN and FAK as predictive markers revealed that lesions with strong expression of either one (group 1) or both proteins (group 2) reflected a significantly higher cancer risk than those with weak to moderate expression (group 0) (log-rank P = .008, group 2 versus 0; P < .001, group 1 versus 0; Fig 3E) ; however, strong expression of both proteins together did not correspond to a higher cancer risk compared to a single protein (log-rank P = .195, group 2 versus 1; Fig 3E) . Strong expression of CTTN and/or FAK showed the most robust association with laryngeal cancer risk (logrank P < .001; Fig 3F) . Five years after the patients were diagnosed, 19 (63%)
of the 30 patients with strong expression of CTTN and/or FAK developed laryngeal cancer whereas only 9 (17%) of the 52 patients with weak to moderate expression of these two proteins progressed to invasive carcinoma (P < .001; Table 2 ). In addition, we also found that CCND1 gene amplification but not protein expression significantly associated with a higher risk of progression (P = .009; Table 2 ).
Univariate Cox analysis showed that CTTN and CCND1 gene amplification and CTTN and FAK expression but not histological grading were significantly associated with laryngeal cancer risk ( Table 3 Given that CCND1 gene is located close to CTTN and both genes are commonly co-amplified in HNSCC (13, 14) we also compared their contribution to malignant transformation using the same series of laryngeal dysplasias. We found that CCND1 amplification strongly correlated with increased laryngeal cancer risk; however, it is still difficult to dissect the impact of each gene when 8 
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